Paper Details

  1. Home
  2. Paper Details

Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder.

Author: GangulyRita, LiebowitzMichael R, ManleyAmy L, PadmanabhanSudharshan K, TourianKaren A, TummalaRaj

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Desvenlafaxine 50 mg/day was associated with significantly greater improvement in Hamilton Rating Scale for Depression scores compared with placebo. Desvenlafaxine 100 mg/day was well-tolerated and demonstrated significant improvement on secondary efficacy measures.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To assess the efficacy, safety, and tolerability of 50- and 100-mg/day doses of desvenlafaxine (administered as desvenlafaxine succinate), a serotonin-norepinephrine reuptake inhibitor, for the treatment of major depressive disorder (MDD). RESEARCH DESIGN AND METHODS: Patients with Diagn...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1185/03007990802161923

データ提供：米国国立医学図書館（NLM）

Desvenlafaxine: A Promising Treatment for Major Depressive Disorder

This study explores the efficacy, safety, and tolerability of desvenlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), in treating major depressive disorder (MDD). Like a skilled cartographer charting a vast and complex terrain, researchers sought to map the therapeutic potential of desvenlafaxine, examining its impact on mood and overall well-being. This study is like a compass, guiding us towards a better understanding of this medication's potential role in treating MDD.

Desvenlafaxine: A Viable Option for MDD

The study's findings demonstrate the efficacy of desvenlafaxine in treating MDD, with both 50mg and 100mg doses showing significant improvements in depressive symptoms compared to placebo. This research highlights the potential of desvenlafaxine as a valuable treatment option for individuals with MDD, offering a glimmer of hope in the fight against this debilitating condition.

A Path Towards Better Mental Health

This research provides valuable insights into the effectiveness of desvenlafaxine in treating MDD, highlighting the potential of this medication to improve the lives of individuals struggling with this complex condition. The study's findings are a beacon of hope, pointing towards a brighter future for those seeking relief from depressive symptoms. This knowledge is like a refreshing oasis in the desert of mental health challenges, offering a path towards a more fulfilling and meaningful life.

Dr. Camel's Conclusion

This study takes us on a journey through the challenging desert of major depressive disorder (MDD), revealing the potential of desvenlafaxine as a valuable treatment option. Like a skilled desert guide, researchers navigated the complex terrain of MDD, uncovering the medication's efficacy and safety profile. This research offers a glimmer of hope for individuals struggling with this condition, providing a potential path towards a brighter future.

Date :
  1. Date Completed 2008-08-11
  2. Date Revised 2022-03-21
Further Info :

Pubmed ID

18507895

DOI: Digital Object Identifier

10.1185/03007990802161923

Related Literature

Article Analysis
・Side Effects of desvenlafaxine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.